摘要
目的：检测miR-155在子宫内膜癌患者血清中的表达水平，探讨miR-155表达检测作为诊疗子宫内膜癌分子标志物的的临床意义。方法：以2008年1月-2012年12期间在我院诊治的52例子宫内膜癌患者为研究对象，作为观察组。并以50名健康体检志愿者外周血作为正常对照组。分别检测并对比分析2组研究对象血清中miR-155的表达水平。结果：相对于健康志愿者，子宫内膜癌患者血清miR-155表达水平为（3.87±0.69）倍（P〈0.01）；I-II期子宫内膜癌患者血清中miR-155表达水平为（4.87±0.39）倍；III-IV期子宫内膜癌患者血清中miR-155表达水平为（7.27±0.77）倍，两组比较，在统计学上有显著性差异（P〈0.01）；52例子宫内膜癌患者中， miR-155表达水平相对低的患者的死亡率为8%。而表达水平相对高的患者的死亡率为25.93%（P〈0.01）。结论：miR-155参与了癌细胞的发生、发展，可作为子宫内膜癌的诊断提供辅助诊断价值。
Objective：To detect theexpression levels of miR-155 in serum of patients with endometrial cancer, the expression of miR-155 and clinical significance of the detection of endometrial cancer as molecular markers.Methods：January 2008-December 2012 period in our hospital 52 cases of endometrial cancer patients for the study, as the observation group. And peripheral blood of 50 healthy volunteers served as normal controls. Were detected and analyzed two groups studied the serum levels of miR-155 expression.Results：Compared with healthy volunteers, patients with endometrial cancer serum miR-155 expression level was （3.87±0.69）%（P〈0.01）;the expression of I-II miR-155 in serum of patients with endometrial carcinoma （4.87±0.39） level in serum of patients with times;stage III-IV endometrial carcinoma miR-155 expression level was （7.27±0.77） times, the two groups, there was significant difference in Statistics （P〈0.01）;52 cases of endometrial cancer patients, miR-155 expression in patients with relatively low levels of mortality was 8%. But the expression level in patients with relatively high mortality was 25.93% （P〈0.01）. Conclusion： miR-155 is involved in the early development, cancer cell proliferation, apoptosis and a series of process, can be used as the diagnosis of endometrial cancer new molecular marker.
出处
《中国医药导刊》
2014年第1期160-161,共2页
Chinese Journal of Medicinal Guide
